Success Metrics

Clinical Success Rate
84.8%

Based on 128 completed trials

Completion Rate
85%(128/151)
Active Trials
7(4%)
Results Posted
59%(76 trials)
Terminated
23(13%)

Phase Distribution

Ph early_phase_1
1
1%
Ph phase_1
66
38%
Ph phase_3
10
6%
Ph not_applicable
2
1%
Ph phase_2
95
54%

Phase Distribution

67

Early Stage

95

Mid Stage

10

Late Stage

Phase Distribution174 total trials
Early Phase 1First-in-human
1(0.6%)
Phase 1Safety & dosage
66(37.9%)
Phase 2Efficacy & side effects
95(54.6%)
Phase 3Large-scale testing
10(5.7%)
N/ANon-phased studies
2(1.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.5%

128 of 159 finished

Non-Completion Rate

19.5%

31 ended early

Currently Active

7

trials recruiting

Total Trials

175

all time

Status Distribution
Active(8)
Completed(128)
Terminated(31)
Other(8)

Detailed Status

Completed128
Terminated23
unknown8
Withdrawn8
Active, not recruiting6
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
175
Active
7
Success Rate
84.8%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (0.6%)
Phase 166 (37.9%)
Phase 295 (54.6%)
Phase 310 (5.7%)
N/A2 (1.1%)

Trials by Status

unknown85%
completed12873%
active_not_recruiting63%
not_yet_recruiting11%
terminated2313%
recruiting11%
withdrawn85%

Recent Activity

7 active trials
Showing 5 of 175
active_not_recruitingphase_1

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

NCT01660971
active_not_recruitingphase_1

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

NCT00878163
active_not_recruitingphase_3

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

NCT02193282
active_not_recruitingphase_1

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

NCT00045201
completedphase_3

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

NCT01013649
View all 175 trials

Clinical Trials (175)

Showing 20 of 175 trialsScroll for more
NCT01660971Phase 1

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Active Not Recruiting
NCT00878163Phase 1

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Active Not Recruiting
NCT02193282Phase 3

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Active Not Recruiting
NCT00045201Phase 1

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Active Not Recruiting
NCT01013649Phase 3

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Completed
NCT01708954Phase 2

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Active Not Recruiting
NCT03137771Phase 2

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Active Not Recruiting
NCT04172779Phase 2

Erlotinib for Hepatocellular Carcinoma Chemoprevention

Not Yet Recruiting
NCT00885066Phase 1

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Completed
NCT00954226Phase 1

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Completed
NCT06997068Phase 2

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Recruiting
NCT02535338Phase 1

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Completed
NCT00720304Phase 2

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Completed
NCT01064479Phase 2

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Completed
NCT00254384Phase 1

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

Completed
NCT02273362Phase 1

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

Completed
NCT01068587Phase 1

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Completed
NCT00079053Phase 1

Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Completed
NCT02154490

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Completed
NCT01332279Phase 1

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
175